The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Long-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Open accessAbstract
Dopamine, the major neurotransmitter depleted in Parkinson disease, can be synthesized and regulated in vivo with a combination of intrastriatal AAV-hAADC gene therapy and administration of the dopamine precursor l-Dopa. When tested in MPTP-lesioned monkeys, this approach resulted in long-term improvement in clinical rating scores, significantly lowered l-Dopa requirements, and a reduction in l-Dopa-induced side effects. Positron emission tomography with [(18)F]FMT confirmed persistent AADC activity, demonstrating for the first time that infusion of AAV vector into primate brain results in at least 6 years of transgene expression. AAV-hAADC restores the ability of the striatum to convert l-Dopa into dopamine efficiently. Introduction of this therapy into the clinic holds promise for Parkinson patients experiencing the motor complications that result from escalating l-Dopa requirements against a background of disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
Marsden, C. D., & Parkes, J. D. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91146-1 · Cited by 587
Gibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
Adeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500
Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406
Self-citationThe neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd, K. G., Davidson, L., & Hornykiewicz, O. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30363-0 · Cited by 396
AGID, Y., JAVOY, F., & GLOWINSKI, J. (1973) · Nature New Biology · doi:10.1038/newbio245150a0 · Cited by 366
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Current Protocols in Neuroscience
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142301 · Cited by 323
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Self-citationThe Scientific Basis for the Current Treatment of Parkinson's Disease
Olanow, C. W. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104422 · Cited by 170
Imbert, C., Bézard, E., Guitraud, S., Boraud, T., & Gross, C. E. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(99)00184-3 · Cited by 163
Synaptic organization of the striatum
Gerfen, C. R. (1988) · Journal of Electron Microscopy Technique · doi:10.1002/jemt.1060100305 · Cited by 161
Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies
Mouradian, M. M., Juncos, J. L., Fabbrini, G., & Chase, T. N. (1987) · Annals of Neurology · doi:10.1002/ana.410220406 · Cited by 136
Hadaczek, P., Kohutnicka, M., Krauze, M. T., Bringas, J., Pivirotto, P., Cunningham, J., & Bankiewicz, K. S. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.291 · Cited by 119
Self-citationA Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian Monkeys
Forsayeth, J., Eberling, J. L., Sanftner, L. M., Zhen, Z., Pivirotto, P., Bringas, J., Cunningham, J., & Bankiewicz, K. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.008 · Cited by 103
Self-citationSanftner, L. M., Sommer, J. M., Suzuki, B. M., Smith, P. H., Vijay, S., Vargas, J. A., Forsayeth, J., Cunningham, J., Bankiewicz, K. S., Kao, H., et al. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.03.007 · Cited by 83
Self-citationRecombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
Jf, W., Qu, G., Tang, C., & Sommer, J. M. (2003) · PubMed · Cited by 81
Demonstration of l-dopa decarboxylating neurons specific to human striatum
Ikemoto, K., Kitahama, K., Jouvet, A., Arai, R., Nishimura, A., Nishi, K., & Nagatsu, I. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00587-9 · Cited by 66
Striatal plasticity and extrapyramidal motor dysfunction
Chase, T. N. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.02.012 · Cited by 51
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys
Bankiewicz, K. S., Daadi, M. M., Pivirotto, P., Bringas, J., Sanftner, L. M., Cunningham, J., Forsayeth, J., & Eberling, J. L. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.022 · Cited by 49
Self-citationA novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes
Eberling, J. L., Jagust, W. J., Taylor, S., Bringas, J., Pivirotto, P., VanBrocklin, H. F., & Bankiewicz, K. S. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00710-0 · Cited by 39
Self-citationChapter 10 Aromatic L-amino acid decarboxylase modulation and Parkinson's disease
Neff, N. H., & Hadjiconstantinou, M. (1995) · Progress in brain research · doi:10.1016/s0079-6123(08)61206-6 · Cited by 35
Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys
Daadi, M. M., Pivirotto, P., Bringas, J., Cunningham, J., Forsayeth, J., Eberling, J. L., & Bankiewicz, K. S. (2006) · Neuroreport · doi:10.1097/01.wnr.0000198952.38563.05 · Cited by 34
Self-citationAminoff, M. J. (2001) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70008-6 · Cited by 11
Doroudchi, M. M., Liauw, J. A., Heaton, K., Zhen, Z., & Forsayeth, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03048.x · Cited by 9
Self-citation
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Metadata
- Authors
- Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., & Cunningham, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 14
- Issue
- 4
- Pages
- 564-570
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2095401453
- Cited by
- 282
- References
- 30
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.